Freedom Investment Management Inc. Raises Stock Holdings in Pfizer Inc. (NYSE:PFE)

Freedom Investment Management Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 67.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,737 shares of the biopharmaceutical company's stock after purchasing an additional 12,792 shares during the quarter. Freedom Investment Management Inc.'s holdings in Pfizer were worth $842,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Forum Financial Management LP grew its holdings in shares of Pfizer by 56.8% in the 4th quarter. Forum Financial Management LP now owns 96,645 shares of the biopharmaceutical company's stock valued at $2,564,000 after buying an additional 35,001 shares during the period. Belmont Capital LLC raised its position in Pfizer by 20.9% during the fourth quarter. Belmont Capital LLC now owns 11,300 shares of the biopharmaceutical company's stock worth $300,000 after acquiring an additional 1,957 shares in the last quarter. Capital International Ltd. CA lifted its stake in Pfizer by 3.5% in the 4th quarter. Capital International Ltd. CA now owns 253,273 shares of the biopharmaceutical company's stock valued at $6,719,000 after purchasing an additional 8,509 shares during the last quarter. Capital International Sarl boosted its holdings in shares of Pfizer by 3.6% during the 4th quarter. Capital International Sarl now owns 356,477 shares of the biopharmaceutical company's stock worth $9,457,000 after buying an additional 12,495 shares during the period. Finally, Adams Wealth Management boosted its holdings in shares of Pfizer by 22.3% during the fourth quarter. Adams Wealth Management now owns 22,976 shares of the biopharmaceutical company's stock worth $610,000 after acquiring an additional 4,191 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.3 %

NYSE:PFE traded down $0.07 during trading hours on Monday, reaching $22.07. The company had a trading volume of 31,814,050 shares, compared to its average volume of 40,452,372. The business's 50-day simple moving average is $24.81 and its two-hundred day simple moving average is $26.11. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The firm has a market cap of $125.17 billion, a price-to-earnings ratio of 15.65, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The company's quarterly revenue was up 24.7% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the transaction, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PFE has been the topic of several analyst reports. UBS Group reduced their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res raised Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.